Nasal Sprays Target the Main Entry Point of the Influenza Virus Tatyana Maksimova/Getty Images
Recent research highlights a novel antibody nasal spray that showed promise in early trials with mice, monkeys, and humans for preventing influenza infections. This spray can neutralize various strains of influenza viruses, including those transmitted from animals, potentially aiding in the fight against future pandemics.
The primary method of combating the spread of influenza remains the annual vaccine, designed to stimulate the immune system to produce targeted antibodies against circulating virus strains. However, due to the constant mutations of influenza viruses, vaccines can only offer limited protection.
To enhance vaccine efficacy, pharmaceutical innovator Johnson & Johnson has developed a groundbreaking antibody, CR9114, capable of neutralizing diverse influenza strains. This antibody recognizes and binds to invariant components of the virus, allowing for consistent defense against mutations.
Initially, CR9114 was injected into animals, but it didn’t provide adequate protection due to insufficient concentrations reaching the nasal cavity—the virus’s primary point of entry. In 2022, the Leiden Institute licensed CR9114, creating a formulation suitable for nasal administration.
Subsequent studies demonstrated that administering CR9114 via nasal spray to mice and macaque monkeys shielded them from various influenza A and B strains, including one isolated during the 1933 flu outbreak.
In addition, preliminary tests involving 143 individuals aged 18 to 55 revealed that using the nasal spray twice daily maintained steady antibody levels in their nasal passages, showing no significant side effects. Mucus samples collected afterward successfully neutralized different strains of influenza, including the avian flu strain that affected humans in China in 2013.
The next phase of research will expose nasal spray users to live influenza viruses to determine its actual effectiveness in preventing illness.
While nasal sprays may not guarantee 100% effectiveness against all entry routes of the virus, they remain a crucial defense mechanism against influenza. According to Linda Wakim from the University of Melbourne, “Even if you block entry through the nose, you’ll still be eliminating the virus at its main access point for infection.”
Wakim also notes that while the nasal spray may require more frequent dosing than a standard flu shot, it could significantly benefit high-risk populations, such as immunocompromised individuals and frontline health workers, especially during pandemics when rapid public health responses are essential.
Topics:
Source: www.newscientist.com
